Surufatinib Approved in China For the Treatment of Pancreatic Neuroendocrine Tumors
The National Medical Products Administration (NMPA) of China has recently approved surufatinib for drug registration for the treatment of advanced pancreatic neuroendocrine tumors (pNETs). HUTCHMED Limited recently announced the news,…